Get the latest tech news
The Crackdown on Compounded GLP-1 Meds Has Begun
Eli Lilly and Novo Nordisk are leading efforts to curb the sale of compounded GLP-1 medications. Lilly has issued hundreds of cease-and-desist letters to entities selling compounded tirzepatide, following the end of its FDA-declared shortage. Novo Nordisk, whose semaglutide drugs remain in shortage,...
Lilly has issued hundreds of cease-and-desist letters to entities selling compounded tirzepatide, following the end of its FDA-declared shortage. The company published a peer-reviewed study in Pharmaceutical Research, highlighting quality concerns in compounded semaglutide samples, including lower-than-claimed strength and banned ingredients. Wired adds: With mounting evidence that GLP-1s like tirzepatide are an effective treatment for other ailments beyond obesity and diabetes -- including addiction and Parkinson's disease -- demand is only expected to increase.
Or read this on Slashdot
